Drug Trial Radar · NCT07674862
Safety, Tolerability and Pharmacokinetics of ETD-001 Gel
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
56
Actual
Start
Mar 16, 2026
Primary completion
Jul 5, 2026
Study completion Aug 30, 2026
Sponsor
- Lead sponsor
- Etern Therapeutics Wuxi LimitedAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Other
- FDA-regulated drug
- No
- Who can join
- All sexes, from 16 years, up to 60 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind, placebo-controlled Phase I clinical study, which comprises two parts: Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) in healthy subjects.Three dose groups are pre-scheduled for the SAD part. After the safety and tolerability of subjects in the second SAD dose group are confirmed, the MAD part will be initiated upon evaluation by the Safety Review Committee (SRC). Four dose groups are tentatively planned for the MAD part.Each dose group will enroll 8 subjects, who will be randomized at a 6:2 ratio to receive either ETD-001 gel or placebo.
Conditions
- Safety Issues
Interventions
Dose 1Drug
low dose
dose 2Drug
middle dose
dose 3Drug
high dose
Primary outcomes
What the sponsor says the trial is designed to measure.
- To evaluate the safety and tolerability of ETD-001 in healthy Chinese subjects.Time frame: Up to Day 21
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hangzhou
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.